• Forum
  • Aktiemarkeder
    • MarkederRealtidskurser, indekser og markedsudvikling
    • BørskalenderKommende resultater, noteringer og virksomhedsbegivenheder
    • UdbyttekalenderKommende og tidligere udbytter
  • Selskaber
    • SelskaberGennemse og filtrer den fulde liste over børsnoterede selskaber
    • OpdagInspiration til din næste investering
    • BørsnoteringerNye noteringer og kommende børsintroduktioner
    • Invitationer til generalforsamlingerDatoer for generalforsamlinger og aktionærinformation
  • Aktieanalyse
    • ResearchEkspertaktieanalyse og anbefalinger
    • ArtiklerNyheder, indsigter og markedskommentarer
    • inderesTVVideocenter for aktieanalyse, forskning og ekspertkommentarer
    • TransskriptionerFuldstændige udskrifter af resultatopkald og investormøder
    • AktieoversigtSammenlign nøgletal og udvikling på tværs af flere aktier
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer

Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.

Neola Medical

0,84 SEK

-2,33 %

Mindre end 1K følgere

NEOLA

First North Stockholm

Medical Equipment & Services

Health Care

Oversigt
Finansielt overblik og estimater
Ejerskab
Dividend
Investorkonsensus
Sammenligne
-2,33 %
-26,92 %
+2,31 %
-17,96 %
-23,72 %
-62,19 %
-52,74 %
-73,98 %
-84,33 %

Neola Medical operates in the medical technology sector. The company focuses on neonatal care, where it develops medical equipment. Examples of products that the company provides to the healthcare sector include technical monitoring and follow-up of lung capacity in premature infants. In addition to the main product, ancillary products and disposables are offered. The largest operations are found in the Nordic market. Neola Medical was founded in 2016 and is headquartered in Sweden.

Læs mere
Markedsværdi
104,77 mio. SEK
Aktieomsætning
142,04 t SEK
Omsætning
-
EBIT %
-
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin
EPS og udbytte
Finanskalender
21.8
2026

Delårsrapport Q2'26

18.11
2026

Delårsrapport Q3'26

Alle
Selskabsmeddelelser
Eksterne analyser
ViserAlle indholdstyper

Omsætning og EBIT-margin

Omsætning t

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Pressemeddelelse10.6.2026, 05.30

Neola Medical granted Patent in the U.S. for reducing optical noise in lung monitoring measurements

Neola Medical
Pressemeddelelse3.6.2026, 05.30

Neola Medical to Present at Aktiedagarna: Advancing U.S. Market Preparations Following Positive Clinical Safety Results

Neola Medical
Pressemeddelelse20.5.2026, 09.20

Redeye: Neola Medical (Q1 Review): An undramatic report after an eventful period

Neola Medical

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Selskabsmeddelelse19.5.2026, 05.00

Neola Medical Q1 Report 2026 – Positive safety results from clinical study in preterm born babies strengthen the path toward market

Neola Medical
Selskabsmeddelelse21.4.2026, 05.00

Neola Medical Reports Positive Safety Results from First Clinical Pilot Study and Advances Towards Next Phase of Clinical Development

Neola Medical
Pressemeddelelse16.3.2026, 06.05

Neola Medical Completes Enrollment in Swedish Clinical Pilot Study

Neola Medical
Pressemeddelelse13.2.2026, 11.59

Redeye: Neola Medical (Q4 Review): Eyes on upcoming clinical data

Neola Medical
Selskabsmeddelelse12.2.2026, 06.00

Neola Medical Q4 Report 2025 – Advancing IP Protection as a Core Strategic Asset across Key Markets

Neola Medical
Pressemeddelelse5.2.2026, 07.00

Neola Medical invites to presentation of the Q4-report 2025

Neola Medical
Pressemeddelelse17.12.2025, 10.40

Neola Medical’s CEO shares recent company highlights in winter 2025 investor letter

Neola Medical
Selskabsmeddelelse9.12.2025, 06.00

Neola Medical expands leadership team with appointment of Director Disposable Product Development

Neola Medical
Pressemeddelelse2.12.2025, 06.00

Neola Medical granted U.S. patent for disposable probes, strengthening future revenue model in target market

Neola Medical
Pressemeddelelse13.11.2025, 06.00

Neola Medical granted Patent in China for reducing optical noise in lung monitoring measurements

Neola Medical
Pressemeddelelse7.11.2025, 07.37

Redeye: Neola Medical (Q3 Review) - Revised timeline

Neola Medical
Selskabsmeddelelse4.11.2025, 17.57

Neola Medical Q3 Report 2025 – Progressing toward completion of Swedish clinical pilot study and strengthening leadership team

Neola Medical
Selskabsmeddelelse4.11.2025, 17.53

Revised Timeline Announced as Clinical Pilot Study Indicates Robust Safety and Need for Optimization of Neola®

Neola Medical
Pressemeddelelse16.10.2025, 06.00

Neola Medical Strengthens Global IP Portfolio with New Patents Granted in both the U.S. and China for Medical Device Neola®

Neola Medical
Pressemeddelelse1.10.2025, 05.00

Neola Medical’s CEO highlights recent progress in autumn 2025 investor letter

Neola Medical
Selskabsmeddelelse25.9.2025, 05.20

Neola Medical strengthens leadership team with appointment of Clinical Director

Neola Medical
Pressemeddelelse10.9.2025, 05.00

Neola Medical granted European patent enabling lung monitoring beyond preterm born babies

Neola Medical